ArticleBMC veterinary research2023
Oral phage therapy with microencapsulated phage A221 against Escherichia coli infections in weaned piglets.
Article in BMC veterinary research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Pooled it
- From laboratory to clinical application: a narrative review of bacteriophage therapy for antimicrobial-resistant infections in veterinary medicine.Veterinary research communications · 2026Review
- Characterization of Escherichia Phage ND-4 Against Avian PathogenicLife (Basel, Switzerland) · 2026Article
- Impact of phage therapy in post-weaning piglets challenged with ETEC strain in a controlled minitrial.Porcine health management · 2026Article
- Phage-Microbiota Interactions in the Gut: Implications for Health and Therapeutic Strategies.Probiotics and antimicrobial proteins · 2026Review
- Article
- Bacteriophage Therapy: Overcoming Antimicrobial Resistance Through Advanced Delivery Methods.Molecules (Basel, Switzerland) · 2026Review
- Genomic characterization ofFrontiers in microbiology · 2026Article
- Targeting STEC-induced edema disease in weaned piglets: prophylactic oral phage P-GXEC-L2P5 attenuates bacterial colonization, toxin production, and endothelial damage.Veterinary research · 2025Article
- Recent insights on challenges encountered with phage therapy against gastrointestinal-associated infections.Gut pathogens · 2025Review
- Isolation and characterization of Pseudomonas phage HJ01 and its therapeutic efficacy in canine pyoderma.BMC veterinary research · 2025Article
- Bacteriophages as Potential Anti-Pathogenic Agents for Intestinal Health of Weaned Piglets in the Post-Antibiotic Era: An Updated Review.Animals : an open access journal from MDPI · 2025Review
- Effect of temperate bacteriophage vB_SauS_S1 on the adaptability and pathogenicity of Staphylococcus aureus ST398.BMC microbiology · 2025Article
- Applications of bacteriophages in precision engineering of the human gut microbiome.Engineering microbiology · 2025Review
- The role of gut microbiota in diarrhea and its alleviation through microbiota-targeted interventions.Frontiers in microbiology · 2025Review
- Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.Frontiers in antibiotics · 2025Review
- Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections.Infectious disease reports · 2024Review
- Renewed insights into Ackermannviridae phage biology and applications.Npj viruses · 2024Review
- Bacteriophage Therapy in Companion and Farm Animals.Antibiotics (Basel, Switzerland) · 2024Review
- The current state of phage therapy in livestock and companion animals.Journal of animal science and technology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundEscherichia coli (E. coli) is a common pathogen that often causes diarrhea in piglets. Since bacteria are becoming more and more resistant to antibiotics, phages have become a promising alternative therapy. However, the therapy of oral phage often fails to achieve the desired effect. A novel phage named A221 was isolated by using E. coli GXXW-1103 as host strain, characterized by electron microscopy, genomic sequencing and analyzed by measuring lysis ability in vitro.
resultsPhage A221 was identified as a member of Ackermannviridae, Aglimvirinae, Agtrevirus with 153297 bp genome and effectively inhibited bacterial growth in vitro for 16 h. This study was conducted to evaluate the therapeutic effect of oral microencapsulated phage A221 on E. coli GXXW-1103 infections in weaned piglets. The protective effect of phage was evaluated by body weight analysis, bacterial load and histopathological changes. The results showed that with the treatment of phage A221, the body weight of piglets increased, the percentage of Enterobacteriaceae in duodenum decreased to 0.64%, the lesions in cecum and duodenum were alleviated, and the bacterial load in the jejunal lymph nodes, cecum and spleen were also significantly different with infected group (P < 0.001).
conclusionsThe results showed that phage A221 significantly increased the daily weight gain of piglets, reduced the bacterial load of tissues and the intestinal lesions, achieved the same therapeutic effect as antibiotic Florfenicol. Taken together, oral microencapsulated phage A221 has a good therapeutic effect on bacterial diarrhea of weaned piglets, which provides guidance for the clinical application of phage therapy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.